Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3042]

Multiple myeloma In Rwanda: The need for further research

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda

Multiple myeloma In Rwanda: The need for further research ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )

Durable responses in aRCC, how do we optimise treatment?

Prof Roberto Iacovelli and Prof Viktor Grünwald

Durable responses in aRCC, how do we optimise treatment? ( Prof Roberto Iacovelli and Prof Viktor Grünwald )

The combination of regorafenib, nivolumab and SCRT shows promising efficacy as...

Dr Francesco Sclafani - Institut Jules Bordet, Brussels, Belgium

The combination of regorafenib, nivolumab and SCRT shows promising efficacy as neoadjuvant therapy for locally advanced RC ( Dr Francesco Sclafani - Institut Jules Bordet, Brussels, Belgium )

Trifluridine/tipiracil followed by regorafenib can be an effective treatment...

Prof Michel Ducreux - Gustave Roussy Cancer Centre, Paris, France

Trifluridine/tipiracil followed by regorafenib can be an effective treatment sequence in pretreated mCRC ( Prof Michel Ducreux - Gustave Roussy Cancer Centre, Paris, France )

Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful...

Dr Do-Youn Oh - Seoul National University Hospital, Seoul, Korea

Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival in biliary tract cancer patients ( Dr Do-Youn Oh - Seoul National University Hospital, Seoul, Korea )

Research highlights in lung cancer

Dr Meri Muminovic - Memorial Cancer Institute, Miami, USA

Research highlights in lung cancer ( Dr Meri Muminovic - Memorial Cancer Institute, Miami, USA )

Hormonal receptor positive breast cancer adjuvant and metastatic indications

Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA

Hormonal receptor positive breast cancer adjuvant and metastatic indications ( Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA )

Antibody drug conjugates coming to primetime and new agents for breast cancer

Dr Mariana Chavez McGregor - MD Anderson Cancer Center, Houston, USA

Antibody drug conjugates coming to primetime and new agents for breast cancer ( Dr Mariana Chavez McGregor - MD Anderson Cancer Center, Houston, USA )

Pancreatic, hepatic and biliary malignancies

Dr Mike Cusnir - Mount Sinai Medical Center, Miami, USA

Pancreatic, hepatic and biliary malignancies ( Dr Mike Cusnir - Mount Sinai Medical Center, Miami, USA )

Uncommon genetic aberrations NTRK, RET, NRG

Dr Luis E. Raez - Memorial Cancer Institute, Miami, USA

Uncommon genetic aberrations NTRK, RET, NRG ( Dr Luis E. Raez - Memorial Cancer Institute, Miami, USA )

Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced...

Dr Kevin Kalinsky - Winship Cancer Institute, Georgia, USA

Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared to placebo and fulvestrant ( Dr Kevin Kalinsky - Winship Cancer Institute, Georgia, USA )

Isa-VCd induction in NDMM patients with severe renal impairment show no new...

Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece

Isa-VCd induction in NDMM patients with severe renal impairment show no new safety concerns ( Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece )

More from ecancer